Holen Sie sich die Stockscreener-App
560.93
2.82%
15.40
Vorhandelsmarkt:
563.00
2.07
+0.37%
Schlusskurs vom Vortag:
$545.53
Offen:
$546.92
24-Stunden-Volumen:
976.49K
Relative Volume:
0.77
Marktkapitalisierung:
$59.54B
Einnahmen:
$14.09B
Nettoeinkommen (Verlust:
$4.50B
KGV:
14.28
EPS:
39.28
Netto-Cashflow:
$2.96B
1W Leistung:
+2.37%
1M Leistung:
+10.05%
6M Leistung:
-17.51%
1J Leistung:
-47.56%
1-Tages-Spanne:
$546.92
$563.00
1-Wochen-Bereich:
$541.50
$563.00
52-Wochen-Spanne:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances - Yahoo Finance
Morse Asset Management Inc Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's Trading Volume Surges 40.54% to $546 Million Ranking 212th in Stock Market - AInvest
Metastatic Castration-Resistant Prostate Cancer Clinical - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Victory Capital Management Inc. - MarketBeat
Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals - Barchart.com
Beacon Investment Advisory Services Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
M. Kulyk & Associates LLC Acquires 528 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Edgestream Partners L.P. Sells 6,573 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s New Trial: A Game-Changer for Lung Cancer Treatment? - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Sells 21,337 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Y Intercept Hong Kong Ltd Has $6.16 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. Stock Analysis and ForecastExplosive trading growth - jammulinksnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Los Angeles Capital Management LLC - MarketBeat
What drives Regeneron Pharmaceuticals Inc. stock priceOutstanding capital appreciation - jammulinksnews.com
Evergreen Wealth Management LLC Invests $3.59 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Balentine LLC Makes New $680,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Neutralizing Antibody Market Surges with Monoclonal Therapy & - openPR.com
South Dakota Investment Council Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Private Advisor Group LLC Has $9.05 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What analysts say about Regeneron Pharmaceuticals Inc. stockSuperior trading gains - printweek.in
Is Regeneron Pharmaceuticals Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
678 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by AustralianSuper Pty Ltd - MarketBeat
Apollon Wealth Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co. - MarketBeat
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. - The Motley Fool
Cwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer? - TipRanks
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer? - TipRanks
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? - The Globe and Mail
Bailard Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet? - 富途牛牛
Wealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Las bolsas europeas suben, con el foco en los resultados - Yahoo Finanzas
Concord Asset Management LLC VA Purchases 972 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 47,567 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cutter & CO Brokerage Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis - TipRanks
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Regeneron’s Promising Obesity Treatment Study: A Potential Game-Changer? - TipRanks
Red Biotechnology Market Attracts Investments from Major - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth Partners - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):